Nebulized salbutamol for asthma: Effects on serum potassium and phosphate levels at the 60 min

Basit Öğe Kaydı
dc.authoridkarakus, ali/0000-0003-1358-3201
dc.contributor.authorSahan, M.
dc.contributor.authorYilmaz, M.
dc.contributor.authorGokel, Y.
dc.contributor.authorErden, E. S.
dc.contributor.authorKarakus, A.
dc.date.accessioned2024-09-18T20:56:49Z
dc.date.available2024-09-18T20:56:49Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: We conducted this prospective study to expand available information in relation to serum phosphate levels in treatment of acute asthma. A beta-adrenergic agonist, salbutamol, was used for this purpose. Material and methods: Twenty-six patients who met the inclusion criteria as; age over 16 years, asthma history, and an acute exacerbation were included. Serum blood urea nitrogen, creatinine, glucose were within normal limits in all the patients. None of the patients were on chronic theophylline therapy. Baseline serum phosphate and potassium levels were measured. Nebulized salbutamol (2.5 mg) was used three times at every hour. After 60 min, serum phosphate and potassium levels were measured. Results: Serum phosphate levels decreased from 3.7 +/- 0.9 mg/dL (baseline) to 3.6 +/- 0.9 mg/dL at 60 min. This decrease was not statistically significant (p=0.373). Serum potassium levels decreased significantly (p < 0.001) from 4.6 +/- 0.7 mmol/L (baseline) to 4.3 +/- 0.7 mmol/L (60 min). Conclusion: Administration of nebulized salbutamol during the emergency treatment of acute exacerbation of asthma is not associated with a statistical decrease in serum phosphate. There was significant hypokalemia. This study indicates that a further study is needed to elucidate the clinical significance of nebulized salbutamol on serum phosphate. (c) 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.en_US
dc.identifier.doi10.1016/j.rppneu.2012.12.003
dc.identifier.endpage203en_US
dc.identifier.issn0873-2159
dc.identifier.issue5en_US
dc.identifier.pmid23659992en_US
dc.identifier.scopus2-s2.0-84888190033en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage200en_US
dc.identifier.urihttps://doi.org/10.1016/j.rppneu.2012.12.003
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12096
dc.identifier.volume19en_US
dc.identifier.wosWOS:000325382700004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Doyma Slen_US
dc.relation.ispartofRevista Portuguesa De Pneumologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSalbutamolen_US
dc.subjectPhosphateen_US
dc.subjectAsthmaen_US
dc.titleNebulized salbutamol for asthma: Effects on serum potassium and phosphate levels at the 60 minen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
229.26 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu